Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

It was 2012, and Doug Chap­nick was fed up with tra­di­tion­al bio­chem­istry re­search.

That kind of think­ing first led him to a De­part­ment of De­fense-fund­ed project, which in­volved white pow­ders and Rube Gold­berg-es­que ex­per­i­ments, and then to found­ing a biotech com­pa­ny called Bi­oLoomics, which is try­ing to de­vel­op new pro­tein de­graders via di­rect­ed evo­lu­tion, or lab-based nat­ur­al se­lec­tion, in hu­man cell ex­per­i­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER